



Published in final edited form as:

Eur J Cancer. 2018 November ; 103: 287. doi:10.1016/j.ejca.2018.09.022.

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [*Eur J Cancer* 94 (May 2018) 115–125]

Toni K. Choueiri^{a,*}, Colin Hessel^b, Susan Halabi^c, Ben Sanford^d, M. Dror Michaelson^e, Olwen Hahn^f, Meghara Walsh^a, Thomas Olencki^g, Joel Picus^h, Eric J. Smallⁱ, Shaker Dakhil^j, Darren R. Feldman^k, Milan Mangeshkar^b, Christian Scheffold^b, Daniel George[#], and Michael J. Morris^{#k}

^aDana-Farber/Partners CancerCare, Boston, MA, USA

^bExelixis Inc., South San Francisco, CA, USA

^cDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA

^dAlliance Statistics and Data Center, Duke University, Durham, NC, USA

^eMassachusetts General Hospital Cancer Center, Boston, MA, USA

^fAlliance Protocol Operations Office, Chicago, IL, USA

^gThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

^hSiteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA

ⁱUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

^jUniversity of Kansas – Wichita, Wichita, KS, USA

^kMemorial Sloan Kettering Cancer Center, New York, NY, USA

^lDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA

These authors contributed equally to this work.

The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined):

As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group).

The authors would like to apologise for any inconvenience caused.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* *Corresponding author*: Dana Farber Cancer Institute, 450 Brookline Avenue, DANA 1230, Boston, MA 02215, USA. Fax: +1 617 632 2165., toni_choueiri@dfci.harvard.edu (T.K. Choueiri).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript